Chromocell Therapeutics (Chromocell Therapeutics) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Debt-to-Asset?

Chromocell Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Chromocell Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Chromocell Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $4.03 Mil. Chromocell Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Chromocell Therapeutics Debt-to-Asset Historical Data

The historical data trend for Chromocell Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Debt-to-Asset Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

3.36

9.82

13.22

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial							15.08	11.99	52.13	13.22	-

Competitive Comparison of Chromocell Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Chromocell Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chromocell Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's Debt-to-Asset falls into.

Chromocell Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Chromocell Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.269	+	0)	/	0.096
	=	13.22

Chromocell Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	4.032
	=	0.00

Chromocell Therapeutics (AMEX:CHRO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Chromocell Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.